@article{TCR10140,
author = {Tejpal Gupta},
title = {Resistance mechanisms in glioblastoma stem cells: finding opportunities in challenges},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 4},
year = {2016},
keywords = {},
abstract = {Glioblastoma remains the most aggressive and devastating form of primary brain tumor with universally dismal survival outcomes despite multi-modality management, essentially rendering it incurable in contemporary neuro-oncologic practice. It displays all the classical hallmarks of cancer including immune suppression, sustained proliferative signalling, inhibition of apoptosis, angiogenesis and invasion (1,2). Glioblastoma is biologically very heterogeneous; this intra-tumoral heterogeneity is explained by the stochastic model (2,3), wherein the tumor arises from a single clone of cells with further progression resulting from random accumulation of somatic mutations in genetically unstable cell population and sequential selection of malignant sub-clones through micro-environment cues. The current standard of care for newly-diagnosed glioblastoma comprising maximal safe resection followed by post-operative focal conformal radiotherapy to the tumor bed with concurrent and adjuvant temozolomide chemotherapy, results in a median survival of around 15 months and a 5-year overall survival rarely exceeding 8–10% (4).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/10140}
}